Abstract
Busulfan (BU) is an alkylating agent commonly administered in a pre-conditioning hematopoietic stem cell transplantation (HSCT). BU is a drug with narrow therapeutic index and high interindividual variability in pharmacokinetics. Therapeutic monitoring of oral BU is necessary for success of bone marrow transplantation and it is already well described in literature. Conventional therapeut…